KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Prepaid Assets (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Prepaid Assets data on record, last reported at $474.8 million in Q4 2025.

  • For Q4 2025, Prepaid Assets rose 35.97% year-over-year to $474.8 million; the TTM value through Dec 2025 reached $474.8 million, up 35.97%, while the annual FY2025 figure was $474.8 million, 35.97% up from the prior year.
  • Prepaid Assets reached $474.8 million in Q4 2025 per REGN's latest filing, down from $595.6 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $681.9 million in Q2 2024 and bottomed at $213.6 million in Q1 2021.
  • Average Prepaid Assets over 5 years is $458.5 million, with a median of $444.3 million recorded in 2021.
  • Peak YoY movement for Prepaid Assets: skyrocketed 109.02% in 2021, then tumbled 37.23% in 2023.
  • A 5-year view of Prepaid Assets shows it stood at $482.0 million in 2021, then fell by 14.69% to $411.2 million in 2022, then decreased by 5.98% to $386.6 million in 2023, then fell by 9.67% to $349.2 million in 2024, then surged by 35.97% to $474.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Prepaid Assets were $474.8 million in Q4 2025, $595.6 million in Q3 2025, and $574.3 million in Q2 2025.